SGMO (Sangamo) סך נכסי הפעילות העסקית

Sangamo Therapeutics (SGMO) is accumulating rare genome modification experts, ensuring zero staff turnover within R&D. Business revenues rely on the implementation of gene therapy, particularly drugs targeting Alzheimer's disease. This chart of total assets, which currently stand at 82.92, complements the profile of a team of medical pioneers forming strategic alliances with global pharmaceutical behemoths.

Sangamo Therapeutics (SGMO) is developing an innovative "zinc finger" platform for precision genome editing. This indicator reflects the actual value of all company assets, excluding market speculation. By analyzing the history of controlled resources on GURU.Markets, an investor can see a reverse calculation via ROA that combines equity and liabilities. This metric's trend allows for an assessment of the funding efficiency for the development of therapies for Fabry disease and CNS disorders.